Online citations, reference lists, and bibliographies.

Use Of Oral Corticosteroids And Risk Of Fractures.

T. V. van Staa, H. Leufkens, L. Abenhaim, B. Zhang, C. Cooper
Published 2000 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Treatment with oral corticosteroids is known to decrease bone density but there are few data on the attendant risk of fracture and on the reversibility of this risk after cessation of therapy. A retrospective cohort study was conducted in a general medical practice setting in the United Kingdom (using data from the General Practice Research Database [GPRD]). For each oral corticosteroid user aged 18 years or older, a control patient was selected randomly, who was matched by age, sex, and medical practice. The study comprised 244,235 oral corticosteroid users and 244,235 controls. The average age was 57.1 years in the oral corticosteroid cohort and 56.9 years in the control cohort. In both cohorts 58.6% were female. The most frequent indication for treatment was respiratory disease (40%). The relative rate of nonvertebral fracture during oral corticosteroid treatment was 1.33 (95% confidence interval [CI], 1.29-1.38), that of hip fracture 1.61 (1.47-1.76), that of forearm fracture 1.09 (1.01-1.17), and that of vertebral fracture 2.60 (2.31-2.92). A dose dependence of fracture risk was observed. With a standardized daily dose of less than 2.5 mg prednisolone, hip fracture risk was 0.99 (0.82-1.20) relative to control, rising to 1.77 (1.55-2.02) at daily doses of 2.5-7.5 mg, and 2.27 (1.94-2.66) at doses of 7.5 mg or greater. For vertebral fracture, the relative rates were 1.55 (1.20-2.01), 2.59 (2.16-3.10), and 5.18 (4.25-6.31), respectively. All fracture risks declined toward baseline rapidly after cessation of oral corticosteroid treatment. These results quantify the increased fracture risk during oral corticosteroid therapy, with greater effects on the hip and spine than forearm. They also suggest a rapid offset of this increased fracture risk on cessation of therapy, which has implications for the use of preventative agents against bone loss in patients at highest risk.
This paper references
Risk fractures for osteoporotic fracture
P D Ross (1998)
10.1164/ajrccm/148.1.113
Effects of short-term inhaled budesonide and beclomethasone dipropionate on serum osteocalcin in premenopausal women.
Judith A. Leech (1993)
Osteoporosis associated with illness and medications
E Shane (1996)
10.1016/S0091-6749(95)70003-X
Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma.
J. Toogood (1995)
10.1016/B978-012470862-4/50033-7
Falls as Risk Factors for Fractures
A. Schwartz (2001)
10.1164/ajrccm.153.3.8630574
Fluticasone propionate does not influence bone metabolism in contrast to beclomethasone dipropionate.
Gerbern P Bootsma (1996)
Research implications of computerised primary care
R D Mann (1992)
10.1016/S0140-6736(73)92964-4
INTRAVENOUS AMINOPHYLLINE AND OSTEOPOROSIS
István Holló (1973)
10.7326/0003-4819-105-1-52
Theophylline-induced hypercalcemia.
Mary Lynn McPherson (1986)
Effects on bone are unlikely with low to moderate dosages: Do inhaled steroids cause osteoporosis
JH Toogood (1998)
Risk fractures for osteoporotic fracture. Osteoporosis27:289–295
PD Ross (1998)
10.1359/jbmr.1998.13.8.1283
Bone mineral density and bone turnover in asthmatics treated with long-term inhaled or oral glucocorticoids.
Peter R. Ebeling (1998)
Research implications of computerised primary care. Post Marketing Surveillance 5:259–268
RD Mann (1992)
10.1136/bmj.293.6560.1463
Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica.
Diane M. Reid (1986)
10.1183/09031936.97.10092110
Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study.
M Luengo (1997)
Bone turnover during high-dose inhaled corticosteroid therapy
NJ Ali (1991)
10.1016/S0140-6736(00)02138-3
Inhaled corticosteroid use and bone-mineral density in patients with asthma
C. Wong (2000)
10.1016/S0091-6749(98)70159-9
Effects of inhaled corticosteroids on bone density and metabolism.
A Woodcock (1998)
Belchetz P 1996 Bone mineral density in women taking inhaled corticosteroids
R J Stead
10.1002/pds.2630010607
Further validation of information recorded on a general practitioner based computerized data resource in the united kingdom
H. Jick (1992)
10.1164/ajrccm.157.3.9703080
Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease.
Charlene E. McEvoy (1998)
Bone mineral density in women taking inhaled corticosteroids
RJ Stead (1996)
10.1016/S0091-6749(95)70254-7
Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids.
N. Hanania (1995)
10.1016/0895-4356(94)00137-F
The VAMP Research multi-purpose database in the U.K.
Y Lis (1995)
10.1136/thx.52.10.853
Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma.
Alice Wisniewski (1997)
10.1214/ss/1177013232
The Role of a Second Control Group in an Observational Study
Paul R. Rosenbaum (1987)
Effect of inhaled corticosteroid on bone density in asthmatic patients: a pilot study.
A H Wolff (1991)
Anonymous 1996 The General Practice Research Database: Information for Researchers
10.1002/pds.2630010108
Pharmacoepidemiology using a UK database of primary care records
Gillian C Hall (1992)
10.1016/S0002-9343(97)90022-X
The crippling consequences of fractures and their impact on quality of life.
Cyrus Cooper (1997)
General Practice Research Database (GPRD): Scope and Quality of Data
J Hollowell (1994)
Comparison of long-term safety and efficacy of fluticasone propionate in combination with salmeterol in patients with moderate to severe asthma
RA Pauwels (1995)
A randomised double blind trial comparing effects of beclomethasone dipropionate 2000/day versus fluticasone propionate 1000/day on bone density over 2 years
J Egan (1995)
10.1136/bmj.307.6895.32
Accuracy of diagnosis of psychosis on general practice computer system.
I. Nazareth (1993)
10.1016/S0140-6736(97)04248-7
The UK General Practice Research Database
T. Walley (1997)
10.1001/archinte.159.9.941
Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis.
B. Lipworth (1999)
10.1016/0091-6749(94)90145-7
Effects of long-term use of high-dose inhaled steroids on bone density and calcium metabolism.
L P Boulet (1994)
10.1136/thx.52.2008.S1
The British Guidelines on Asthma Management1995 Review and Position Statement
(1997)
10.1007/BF00280099
The assessment of the systemic effects of inhaled glucocorticosteroids
Bojan Hamlin Jennings (1991)
10.1056/NEJM199503303321307
Inhaled glucocorticoids for asthma.
P. Barnes (1995)
Further validation of information recorded on a general practitioner based computerised data resource in the United Kingdom. Pharmacoepidemiol Drug Saf1:347–349
H Jick (1992)
10.1136/thx.42.12.962
Vertebral compression fractures and mineral metabolism in chronic obstructive lung disease.
José A Riancho (1987)
10.1136/thx.47.6.414
Bone density in asthmatic patients taking high dose inhaled beclomethasone dipropionate and intermittent systemic corticosteroids.
Geoffrey E. Packe (1992)
10.1111/j.1398-9995.1997.tb05047.x
A comparison of the efficacy and safety of inhaled corticosteroids in asthma.
S. Pedersen (1997)
10.1378/chest.105.6.1722
Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids.
Mary Sau-Man Ip (1994)
Effects of theophylline on urinary excretion of cyclic AMP, calcium, and phosphorus in normal subjects.
Andrew A Colin (1984)
Anonymous 1996 The EPIC Encyclopedia of Clinical Practice. EPIC, the GP Database Research Company
10.1136/bmj.302.6779.766
Validation of information recorded on general practitioner based computerised data resource in the United Kingdom.
H. Jick (1991)
10.1002/jso.1035
Statistical methods in cancer research.
P. Simpson (2001)
10.1002/pds.2630030106
The quality of information recorded on a UK database of primary care records: A study of hospitalizations due to hypoglycemia and other conditions
Tjeerd‐Pieter Van Staa (1994)



This paper is referenced by
10.1007/s00223-010-9363-2
Effects of Alendronate and Strontium Ranelate on Cancellous and Cortical Bone Mass in Glucocorticoid-Treated Adult Rats
Pengfei Sun (2010)
10.1016/j.afos.2020.04.002
Rheumatoid arthritis in tight disease control is no longer risk of bone mineral density loss
Ichiro Yoshii (2020)
10.5812/IJEM.3442
PREVALENCE AND RISK FACTORS FOR NON-VERTEBRAL FRACTURES IN PATIENTS RECEIVING ORAL GLUCOCORTICOIDS
Manuel Sosa Henríquez (2012)
10.1097/MNH.0000000000000233
Skeletal manifestations of renal disease in childhood
Michelle R Denburg (2016)
10.1016/j.jocd.2009.05.003
Osteoporosis risk in patients with chronic obstructive pulmonary disease: the EOLO study.
Stefania Maggi (2009)
10.2147/DHPS.S7197
Management of glucocorticoid-induced osteoporosis: prevalence, and emerging treatment options
Juraj Payer (2010)
ALENDRONATE A PROMISING / MULTI ASPECT DRUG IN THE MANAGEMENT OF OSTOEOPOROSIS
Shehla Shaheen (2011)
10.1016/B978-1-4377-0324-5.00029-8
CHAPTER 29 – Metabolic Bone Disease
Joseph A. Lorenzo (2011)
10.3899/jrheum.110947
Effectiveness of Teriparatide in Postmenopausal Women with Osteoporosis and Glucocorticoid Use: 3-Year Results from the EFOS Study
Dimitrios Karras (2012)
10.1155/2013/768579
Glucocorticoid-Induced Bone Loss Is Associated with Abnormal Intravertebral Areal Bone Mineral Density Distribution
Louise I. Manning (2013)
10.1359/jbmr.091025
Persistent secondary hyperparathyroidism and vertebral fractures in kidney transplantation: role of calcium-sensing receptor polymorphisms and vitamin D deficiency.
Sandro Giannini (2010)
10.1007/978-3-319-75110-8_13
Osteoporosis in Men
Elena Nebot Valenzuela (2018)
10.1136/thx.2003.013839
Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids
Ian A. Campbell (2004)
10.2147/IBPC.S9486
Hypertension and other morbidities with Cushing’s syndrome associated with corticosteroids: a review
Melpomeni Peppa (2011)
A review on safety : published evidence Low-dose glucocorticoid therapy in rheumatoid
Ja Pereira da Silva (2005)
10.1016/S1699-258X(07)73624-0
Osteoporosis inducida por glucocorticoides: ¿qué hay de nuevo?
María Pilar Aguado Acín (2007)
10.1056/NEJMcp1800214
Glucocorticoid‐Induced Osteoporosis
Lenore M. Buckley (2018)
10.1097/00060793-200012000-00005
Glucocorticoid-induced osteoporosis
Ernesto Canalis (2000)
10.1016/j.nephro.2018.07.388
Insuffisance rénale aiguë et boli préemptifs de corticoïdes chez les transplantés rénaux : une étude rétrospective
M. Victor Meunier (2018)
10.1016/j.bone.2020.115405
Cortical thickness relative to the transverse diameter of third metacarpal bone reflects bone mineral density in patients with rheumatoid arthritis.
Ichiro Yoshii (2020)
10.1002/9781119266594.ch41
FRAX: Assessment of Fracture Risk
John A. Kanis (2018)
10.1007/s003930170084
Epidemiologie der Kortikosteroid-induzierten Osteoporose
J Braun (2001)
10.1210/jc.2014-2177
Abnormalities in cortical bone, trabecular plates, and stiffness in postmenopausal women treated with glucocorticoids.
Stephanie A Sutter (2014)
10.1007/s00296-011-2341-9
Prescription for antiresorptive therapy in Mexican patients with rheumatoid arthritis: is it time to reevaluate the strategies for osteoporosis prevention?
J. I. Gamez-Nava (2011)
10.1093/RHEUMATOLOGY/KES079
Quality assurance study of the use of preventative therapies in glucocorticoid-induced osteoporosis in early inflammatory arthritis: results from the CATCH cohort.
Emily McKeown (2012)
The effect of metyrosine/prednisolone combination to oophorectomy-induced osteoporosis
S. Salman (2012)
10.1007/s40520-015-0522-1
Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)
C. Cooper (2016)
10.1007/s00198-011-1713-z
Interpretation and use of FRAX in clinical practice
J. Kanis (2011)
The Incidence of Hip Fracture Associated with Proton Pump Inhibitor (PPI) and/or H2 Receptor Antagonist (H2RA) Use in the Kentucky Medicaid Population
Timothy C. Umeh (2011)
Current indications for prevention and therapy of steroid-iduced osteoporosis in men and women.
Ewa Sewerynek (2011)
10.1007/978-1-4471-2745-1_7
Glucocorticoids, Inflammation, and Bone
Kong Wah Ng (2012)
10.4103/1817-1737.94522
Bone mineral density in asthmatic patients on inhaled corticosteroids in a developing country
Yeh Chunn Kuan (2012)
See more
Semantic Scholar Logo Some data provided by SemanticScholar